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Introduction
There is no doubt that the identification of an
inducible isoform of cyclooxygenase (here re-
ferred to as cyclooxygenase-2 or COX-2) has
brought about a renaissance in prostanoid
biochemistry, pharmacology and therapeutics.
This area is now as vigorous as it was 20 years
ago when thromboxane A2 (TXA2) and prosta-
cyclin (PGI2) were discovered1’2 and indeed is
almost as active as that of nitric oxide (NO),
with which it shares many features and correla-
tions. One of the most important features of
COX-2 is its close association with a variety of
inflammatory mediators and its consequent
description as the COX isoform involved in and
responsible for many of the signs of inflamma-
tion. It is also generally accepted that COX-1 is
the constitutive isoform involved in the physio-
logical actions of prostaglandins (PGs) in the
stomach and kidney, the inhibition of which
leads to gastric ulceration and nephropathy as
side effects of anti-inflammatory therapy with
nonsteroidal anti-inflammatory drugs (NSAIDs).
The initial findings and many of the subse-
quent developments are based on the techni-
ques of molecular biology3’4 and are often
expressed in terms unfamiliar to many research-
ers already established in inflammation. Our
purpose in this review is to summarize the
progress made so far in characterizing the
regulation of COX-2, to evaluate its role in
inflammation and, as a consequence, to assess
the utility of the selective inhibitors of COX-2.
In order to establish the appropriate context for
the analysis of regulatory mechanisms, we shall
(C) 1996 Rapid Science Publishers
first consider the molecular biochemistry of
COX-2 and its possible place in physiology. We
shall also refer to work on COX-1 where
necessary.
Molecular Biochemistry of COX-2
Although the early work on COX-2 utilized
animal sources, information relating to the hu-
man form of this enzyme is steadily accumulat-
ing. Since the practical outcome of COX-2
research would be the more efficient alleviation
of human inflammatory conditions, emphasis
will be placed on results obtained with the
human protein, along with data from animal
sources wherever relevant. Here, for clarity and
simplicity, the molecular biochemistry of COX-2
will be considered at three separate levelsmits
DNA, its RNA and the enzyme protein; further
details of the molecular biolog.y 4
of COX-2 are
available in two recent reviews.3’
DNA
The gene for COX-2 is located on chromosome
1 in both human and mouse cells.5-8 The small
size of the COX-2 gene (7.5-9kbp6’7’9) is
compatible with its inclusion in the group of
inducible, immediate early lg0enes, few of which
are over 10 kbp in length. It is relevant here
to note that the human gene for TXA2 synthase
is larger (75 kbp1) and, like that for human
PGI2 synthase, is only weakly (two-fold) in-
ducible. 12’3 The COX-2 gene has ten exons,
one less than that for COX-1.6,v Overall, the
descriptions from different groups, of human
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genomic DNA for COX-26’7’9 are in agreement
and show many similarities between the human
4 gene and the corresponding murine gene,
underlining the close relationship between spe-
cies. The eDNA for human COX-2 was first
derived from HUVEC cells.5 More recently
eDNA prepared from a human line of erythro-
leukaemia cells (HEL cells7) exhibited virtually
an identical sequence with only two nucleotide
differences.
In contrast to the similarity shown so far
between species in the protein coding and 3’-
flanking regions of COX-2 DNA, there are
important species-related differences in the 5’-
flanking region of the COX-2 gene, where the
promoters and transcription factors bind.
Whereas in the human gene there are putative
binding sites for a variety of transcription
factors including AP-2, SP-1, NF-IL6, NFkB and a
cAMP responsive element (CRE) along with a
TATA box and a TPA-response element in the
first intron,6’7’9’6’7 the corresponding region of
the mouse gene appears to lack a CRE,
4 NFkB
or NF-IL6 site,
7 although the others are present.
The rat gene which has over 80% identity with
the mouse gene in this region also lacks CRE,
NFkB or AP-2 sites and a TATA box but includes
a site for NF-IL6. &19 However more recent
analysis of the mouse gene for COX-2 in an
osteoblastic cell line has found an action of and
sites for, NFkB; the same authors have also
20 identified a NFkB binding site in the rat gene.
mRNA
Reflecting the similarity in cDNA for COX-2
across species, there is also considerable similar-
ity in mRNA for COX-2, which at 4 kb is almost
twice the size of that for COX-1 (2.8 kb) in all
21 species so far examined. Since the enzyme
proteins (COX-1 and COX-2) are very similar in
size, just over 600 amino acid residues, most of
the difference in mRNA for COX-1 and COX-2 is
taken up by the extensive 3’-untranslated region
in COX-2 mRNA. This region includes several
copies of the Shaw-Kamen ’instability’ se-
quence, the actual number varying
2
between
species from 14 to 18 in animals.
2 In two
examples of human mRNA, 17 and 22 copies
were found.7’9 These sequences are characteris-
tic of rapidly degraded RNA7’9 and have been
found in the mRNA for other immediate early
proteins.2 However such sequences do not
occur in the mRNA for COX-1 in any species.
Estimates of the half-life of COX-2 mRNA vary
with the cells studied and with the stimuli used
for induction of the protein. In an endothelium-
24 derived cell line (ECV304) with IL-1 as the
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inducing agent, COX-2 mRNA had a half-life of
about 1 h. In the same system with transcrip-
tion blocked, IL-1 was able to prolong the half-
life of existing COX-2 mRNA to about 90 min,
thus contributing also at a post-transcriptional
stage to the overall induction of the enzyme. In
an epithelial cell line (EGV6), COX-2 mRNA
induced by the phorbol ester, TPA, had a half-
life of 30 min. 25- It appears that the ’built-in’
instability of the COX-2 mRNA is an essential
component of the regulation of this protein and
hence of its activity.
Protein structure and function
The COX proteins are very similar, both be-
tween species and between isoforms, as they
both carry out the same two separate catalytic
functions, oxidation of arachidonate to PGG2
and reduction of peroxide, specifically that of
4 26,-27 PGG2 to PGH2. The differences in protein
structure are small and chiefly outside what is
considered to be the catalytically active site.4’26
The two isoforms are almost identical in size,
COX-1 is about 602 residues whereas COX-2
comprises 604 residues. The major differences
in sequence are at the N terminal where COX-2
has 17 less amino acids in the signal peptide
and at the C-terminal where COX-2 has 18 more
residues than COX-1.4’26 The central parts of
the proteins where the catalytic and substrate
binding sites are located, are almost identical.
The tyrosyl groups crucial for the oxidation and
the histidines interacting with the haem group
are all highly conserved as is the serine acety-
lated by aspirin.
(i) Substrate binding sites
There are important functional differences be-
tween the isoforms which suggest that the
active site in COX-2 is larger or has a looser fit
than that in COX-1. This has been deduced from
various mutations at the serine residue, which
is acetylated by aspirin in either enzyme, Ser
28.29 530 in COX-1 or Ser 516 in COX-2. (The
different numbers for similarly placed residues
in the two isoforms is due to the longer N
terminal sequence in COX-l; the numbering for
COX-1 is thus about 14 in advance of that for
COX-2.) Mutation of serine to alanine in either
isoform altered neither Km nor PG production
but did confer protection against the irreversi-
ble inhibition caused by aspirin, since alanine
cannot be acetylated. 29 However, mutation of
serine to asparagine (isosteric with acetylated
serine) has a strikingly differential effect; the
COX-1 mutant lost cyclo-oxygenase activity
whereas the COX-2 mutant retained full activityCyclooxygenase-2 and its regulation in inflammation
and an unchanged Km. Substitution with a larger not important in binding of substrate as marked
amino acid, glutamine, abolished cyclo-oxyge- mutations at this site (Val to Lys or Glu) did not
nase activity in both isoforms. 28’29 materially alter Km for AA of the COX-2
Another indication of the larger active site in protein. 33
COX-2 may be drawn from the effects of aspirin An attempt to exploit the selectivity sug-
on catalytic activity. This compound irreversibly gested by the larger substrate binding site in
inhibits the production of PGs by COX-1 or COX-2 had an unexpected outcome. It was
COX-2 through the acetylation of Ser 530 or Ser argued that, as the acetylation of COX-2 still
516. Nevertheless, acetylated COX-2 but not allows binding of AA to give 15-HETE, acylation
acetylated COX-l, still oxidized arachidonic acid with a larger acyl group should prevent any
(AA) to an alternative product, 15-HETE.28-3 oxidation of AA by encroaching further into the
This finding would suggest that there is space binding area. In the event, the most potent
for AA to bind to acetylated COX-2 close analogue of aspirin was valeryl salicylic acid but
enough to the active site for oxidation to occur it was a selective inhibitor of COX-1 with no
even though the orientation is not adequate for inhibition of COX-2. 34 The explanation for this
the full cyclo-oxygenase reaction to take place, result is still to be put forward.
Further support comes from the effect of It is important to note that in the COX mutant
another substitution of this serine in COX-2, proteins and in the acetylated native COX, the
with methionine; this leads to a ’pseudo-acety- peroxidase activity catalysed by an active site
lated’ form in that the mutant protein shows on the other side of the haem group from that
increased production of 15-HETE but with involved in the formation of PGG2 remains
much reduced COX activity (5-20% of normal) unaffected, demonstrating quite clearly the sep-
and almost 200-fold increase in Km .28’29 Clearly aration of these two activities within the same
with this substitution both the binding affinity protein molecule.29’35’
and the binding mode were affected.
These deductions from biochemical findings (iO Inhibitor binding sites
were compatible with the model of COX-1 Because COX-1 and COX-2 are catalytically and
structure derived from X-ray crystallographic structurally almost identical, it is likely that if
analysis. 1’32 The Ser 530 lies halfway along a selective inhibitors of COX-2 are to be found
tunnel leading up to the active site and it is then these would not bind to any catalytically
relatively easy to imagine how the acetylation of relevant site which would be the same for both
Ser 530 would block access of substrates to the isoforms, but to some other region possibly
active site at the head of the tunnel. On the unique to COX-2. However access to substrate
basis of the biochemical results for COX-2, one must still be denied in order to inhibit COX-2
would assume that Ser 516 either lies further activity. This line of reasoning would explain
within the wall of the tunnel or that in COX-2 why most of the selective COX-2 inhibitors so
there is enough room for AA to ’squeeze past’ far disclosed are not carboxylic acids (as are
the acetyl group and to bind close enough to most COX-1 inhibitors)but interestingly contain
the tyrosine-haem complex to allow oxidation a different common grouping, the sulphon-
to 15-HETE, but not to tare up the configura- amide or sulphone group.
tion which leads to the cyclic endoperoxide Support for this suggestion for different bind-
(PGG2). ing sites for the two types of inhibitors comes
Another possible factor is the residue on the from another mutant of COX-1 in which Arg
opposite side of the tunnel, Ile523 in COX-1 120 was replaced with Glu. 37’38 This positively
which in COX-2 is substituted by a1509, one charged residue (Arg 120) is located at the
methylene group smaller than lie. This location opening of the active site tunnel1 and was
also provides the only difference between the assumed to be the binding site for the carb-
active sites of the two isoforms. It is therefore oxylic acid group in the substrate fatty acids. It
possible that the extra methylene group of lie was also assumed to provide a binding site for
523 creates enough of a narrowing of the the ’old’, carboxylic acid, non-selective, COX
tunnel so that in combination with the acetyl inhibitors. These assumptions were fully con-
group on Ser 530, access to the active site in firmed by the characteristics of the (Arg 120-
COX-1 is essentially prevented. In COX-2, the Glu) mutant COX-l, which showed a 100-fold
presence of Yal 509 would not only allow a higher Km for AA and a much reduced suscept-
wider range of fatty acid configurations to gain ibility to the carboxylic acid inhibitors including
access as substrates in the normal enzyme but indomethacin, flurbiprofen and diclofenac all of
also provide less of a ’choke point’ in the which did not inhibit the mutant enzyme at
acetylated enzyme. Nevertheless, Val 509 was concentrations between 200- and 8000-fold
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higher than their IC50 values for the wild-type
37 However two COX-2 selective corn- enzyme.
pounds, the sulphone DuP 697 and a sulphon-
amide analogue, were more potent as inhibitors
of the mutant enzyme. Although this increased
potency is probably due to the decreased
binding of substrate AA (DuP 697 is a competi-
tive reversible inhibitor of the wild-type COX-1
enzyme), there was clearly no decrease in the
efficacy of the sulphonamide compounds and
hence no loss of their binding to the mutant
protein. In the other report,
38 the Arg 120-Glu
mutant of ovine COX-1 showed no COX activity
at all. Flurbiprofen binding was thus assessed
with the Arg 120-Gln mutant which had 5% of
the wild-type activity. This mutant did not show
time-dependent inhibition and flurbiprofen’s
IC50 value had increased from 5 bM (wild type)
to 1 mM in the mutant. These results are
probably adequate evidence for the importance
of the Arg 120 residue in the binding of the
’old’ non-selective inhibitors but the binding
sites for the COX-2 selective inhibitors still
remain to be determined, although two recent
reports33’39 provide some clues to its location.
In both, mutants of COX-2 have been gener-
ated with Val 509 being changed to lie, as in
COX-l, and, in the mutants, selective COX-2
inhibitors were much less potent and less
capable of causing the time-dependent inhibi-
tion of COX-2, characteristic of wild-type COX-
2. However in one report, 33 the COX-2 selective
inhibitors (nimesulide, DuP697, NS398,
SC58125) were still able to bind and inhibit
presumably on a ’reversible’ basis. The ’old’
NSAIDs were unaffected by this mutation. 39
Here the Val/Ile substitution appears to be
crucial in determining the activity and possibly
selectivity of inhibitors of COX-2. The possible
effects of this substitution have already been
discussed above in terms of substrate access but
it is less easy to visualize the crucial influence
of a methylene group in the binding of strongly
polar sulphone/sulphonamide compounds such
as the selective COX-2 inhibitors. The crystal
structure of human recombinant COX-2 was
described at a recent meeting
4 and although
the full report is not yet avai{able some details
relevant to this point have emerged. As ex-
pected the crystal structure of COX-2 is almost
identical to that of COX-1. However for cox-2,
two conformations appear to be possible for
4o the binding of inhibitors, one in which
inhibitor binds to both Arg 120 and Tyr 355
(see Ref. 38) as polar sites (the closed con-
former) and the other (open conformer) in
which inhibitor binding excludes Arg 120. Since
mutants of Arg 120 do not change binding of
COX-2 selective inhibitors, the open conformer
would appear to be the most liRely form of
COX-2 bound to a selective inhibitor. However
these changes are at the mouth of the substrate
tunnel and involve polar residues not the non-
polar Val 509 which has such striking effects on
inhibitor efficacy. It may thus be necessary to
re-assess the role of another polar residue, Glu
524 (in COX-l). This negatively charged amino
acid is close enough in the crystal3’4 to form a
salt bridge with the positively charged Arg 120.
Although Glu 524 was not important for en-.
zymic activity in COX-l, 38 it, along with Tyr 335
could provide polar binding sites in COX-2,
alternative to Arg 120. This residue Glu 524/510
is also immediately adjacent to the lie 523/Val
509 and it may be that the crucial effects of the
Ile/Val substitution on inhibitor binding are
actually to alter the configuration of the next
residue, Glu 524/510. Clearly we need more
information before the binding site for COX-2
selective inhibitors and the nature of the
conformational change associated with their
action are fully elucidated. (See Note Added in
Proof).
The largest difference between the two pro-
teins is the C-terminal extension (18 amino
acids) and the lack of the 17 residues at the N-
terminus in COX-2. Although the C-terminus in
COX-13 and probably in COX-2, is also distant
from the active site, it clearly exerts a consider-
able influence on the function of the enzyme as
site-directed mutations at the extreme C-term-
inal of recombinant COX-1 had unexpectedly
strong effects on activity.
4 Frustratingly, in
COX-1 crystals, the X-ray analysis appears to
extend reliably only to residue 586 of the 600
total residues in the ovine protein.
3 The three-
dimensional structure of this C-terminal exten-
sion in COX-2 has also not been reported
4
although in the full report more information on
this region may be presented. Mutants of COX-2
with alterations in this region will be invaluable
in this analysis.
Another feature of inhibitor interaction with
the COX proteins is the time-dependent irrever-
sibility of some compounds (apart from aspirin).
This varies between inhibitors and isoforms and
is discussed further below but one aspect is
relevant here. An inference from time-depen-
dent and irreversible inhibition is that there
may be chemical reaction between inhibitor
and enzyme, for instance the formation of a
42 Schiff base. These interactions and subse-
quent conformational changes in protein
43 re different structure a from acetylation by
aspirin as all oxidation of AA is prevented, i.e.
there is no formation of 15-HETE as in acety-
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lated COX-2.28-30 The selective, time-dependent receptor family of proteins whose endogenous
inhibition of COX-242-45 would imply that con- ligands are still undefined, although their activ-
formational changes in COX-1 derive from inter- ity as transcription factors is well established. 53
actions different from those that inactivate PGD2, PGJ2 and other related cyclopentenone
COX-2. It is important to note that neither PGs bind to PPAR, and cause the protein to act
reversible nor irreversible inhibitors affect the as a transcription factor for reporter genes54-56
peroxidase activity of the proteins which con- and also to stimulate the differentiation of
tinue to function normally in the presence of fibroblasts into adipocytes. 54’55 These PGs may
the inhibitors. 29’35’36 Another important conse- be the endogenous ligands for the PPARs,
quence of the conformational rearrangement of which might also explain the effects on cell
the enzyme protein with inhibitor would be growth already described for these prost-
that the structure of COX-1 crystallized with anoids.57-59 An intriguing finding is the stimula-
inhibitor31 could be different from that of tion of transcription of the haem oxygenase
enzyme crystallized with substrate, as already gene in rat cells by PGJ2 derivatives6’61 in
recognized.46’47 relation to the possible role of haem oxygenase
62 in the inflammatory response.
(iii) Intracellular location andfunction The extent to which COX-2 accumulates in
The C-terminal region may also be especially this location rather than in the ER could provide
important in securing the protein to the endo- a control mechanism for this growth regulatory
plasmic membranes. For both COX-1 and COX- function, additional to any control of catalytic
2, the most commonly suggested location is in activity by inhibitors. The additional amino-acid
the membrane of the endoplasmic reticulum residues in the C-terminus of COX-2 could be
(ER) with an additional locus for COX-2 on the critical in the location of the enzyme in the
nuclear membrane.48-5 Results from the crys- nuclear membrane and spontaneous mutations
tallographic analysis suggested that the enzyme in this region of the protein might affect the
is bound to the ER by a sequence of short distribution between the ER and nuclear sites.
helical stretches of the molecule which prob- More COX-2 in the nuclear membrane could,
ably only interact with one-half of the lipid for instance, be associated with decreased apop-
bilayer, i.e. there is no transmembrane tosis in epithelial cell lines. 63
structure.3 This description may now need to
be modified. Ren et al.5 using antibodies Physiological and specific for particular sequences in COX-1 Pathophysiological Roles for
protein (including the C-terminus, the active COX-2 site and glycosylation sites), together with
selective lysis of cellular membranes have sug- The accepted role for COX-2 is to provide PGs
gested that the C-terminus may cross the ER in a range of inflammatory and host defence
membrane to the cytoplasm, while agreeing conditions, which could be termed a ’pathologi-
with a luminal location for the rest of the cal’ role. Other functions such as involvement
molecule. Such a model would be compatible in mitogenesis and reproduction inferred from
38 1957 with the crystallographic analysis where the C- experimental results’ could be consid-
terminus beyond Arg 586 was not resolved and ered as physiological or pathophysiological.
other results attributing importance to amino These other roles have been supported by the
acid residues distant from the active site. 4]’52 results from ’knock-out’ animals in which a
Although analogous mutations in COX-2 have gene coding for a particular protein is selec-
not yet been assessed, these findings re-empha- tively inactivated. The logical purpose of knock-
size the importance of the structural analysis of out strains is to expose deficiencies in the
the C-terminal region of the proteins, knock-out animal and from these defects to
The intracellular location of the COX protein deduce the roles played by the missing protein.
is important because only COX-2 is found on In the present context the relevant proteins are
the nuclear membrane where it would be COX-1 and COX-2.
ideally positioned to participate in mitogenesis,
normal or neoplastic. Inflammation A possible mechanism for this participation is
provided by recent findings, in three different Two separate reports64’65 of COX-2 knock-out
systems, of the activation by PGJ2 derivatives of mouse strains (null mice) have appeared and in
the peroxisome proliferator activated receptor each a model of acute inflammation (oedema
type gamma (PPARy). The PPARs (cz, and y) following AA applied to the ear) was used to
are members of the steroid hormone nuclear test responses in the null mice. Both agreed that
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the null mice had normal ear oedema in
response to AA and the interpretation of this
result was that COX-l, still present, was able to
generate the PGs required. Two other models of
acute inflammation (PMA-ear oedema and carra-
geenin paw oedema) also gave normal results in
null mice. The only model tested which failed
in COX-2 null mice was one of LPS-induced
hepatotoxicity which depends on induction of
COX-2 in macrophages and/or Kupffer cells.4
The implications of these experiments in mice
lacking COX-2 are that where COX-1 is normally
present (ear skin, paws) this isoform will substi-
tute for the missing COX-2; where COX-1 is
absent or at very low levels, as in macrophages,
the inducing agent fails to generate the usual
response.
Reproduction and development
An essential role for COX-2 in embryonic
development would be deduced from the
severe morphological defects and consequent
functional failures in the kidneys of COX-2 null
mice,4’5 which lead to their early death (some
at about 8 weeks and most by 6 months). A
similarly absolute requirement for COX-2 in
female fertility must be deduced from the failure
of null female mice to ovulate.4 It is important
to realize that these failures in null mice must
represent a highly localized generation of COX
products as the nature of the products from
COX-2 is the same as those derived from COX-1
and COX-1 is still fully active in the COX-2 null
mice.
A strong linkage between isoform and physio-
logical function was further supported by the
66 results from COX-1 knock-out mice. Here the
null mice are healthy, without developmental
defects and with no ovulatory changes. How-
ever null pups carried by a null mother were
mostly (> 90%) born dead; either a heterozy-
gous mother or some heterozygous pups re-
stored viability of the whole litter to normal.
Clearly the COX-2 prese.nt in the COX-1 null
mice cannot provide the PGs needed for foetal
survival but COX-1 present in some littermates
will ensure survival of all foetuses. Again the
separate events in reproduction appear to have
differing absolute requirements for COX iso-
forms.
Implications of results from knock-
out mice
The possibility of compensatory changes sug-
gested for inflammation in COX-2 knock-out
mice could also explain why in COX-1 null mice
there was no gastric ulceration or NSAID-type
nephropathy. Both these effects would have
been predicted from the known effects of
aspirin and other NSAIDs in normal animals.
However in COX-1 null mice the compensation
was not due to increased amounts of COX-2
activity as gastric tissue from the null mice
synthesized less than 1% of the normal amount
of PGs.66 The most likely alternative compensa-
tion would be from NO; this mediator is, like
PGI2, a vasodilator and ulceration is associated
with vasconstriction in the gastric micro-
circulation. 67 Like COX, both constitutive and
induced NOS can be expressed in endothelium.
One predictable consequence of this alternative
pathway would be that NOS inhibitors would
be ulcerogenic in the COX-1 null mice, whereas
they are not noticeably so in normal animals. 67
If the knock-out mice show that COX-1 and
COX-2 have separate and important physiologi-
cal roles in reproduction and COX-2, unlike
COX-I, plays an essential part in foetal develop-
ment, what do the knock-out mice tell us about
their pathological importance in inflammation?
One conclusion is that there is a clear need for
COX-2 in certain forms of inflammation, per-
haps all those related to the actions of LPS.64
However the logical deduction from the other
results is that COX-2 is not relevant to the
inflammatory models used for many years to
screen for anti-inflammatory compounds. On
the basis of the knock-out results alone, several
major pharmaceutical companies are wasting
time, effort and money in searching for selective
COX-2 inhibitors; these compounds will not
decrease inflammation nor will they affect the
incidence of NSAID-induced gastric ulcers as
that effect is not connected with the presence
or absence of COX-1 activity. In contrast to
these logical deductions, there is a considerable
body of empirical experimental evidence clearly
demonstrating both the anti-inflammatory effi-
cacy of selective COX-2 inhibitors and their
decreased ulcerogenicity when compared with
the more COX-1 selective inhibitors. This para-
dox is not without hope of resolution; there are
still many relevant measurements to be made in
the null strainsmlevels of COX-1 or COX-2
activity, of PEA2 activity, the effect of selective
inhibitors and many othersmand when these
results are gathered, another synthesis of the
apparently opposing views may be possible.
Regulation of COX-2 Activity
It is now clear that the activity of COX-2, as
expressed by the synthesis of PGs, is normally
controlled through the synthesis of the protein.
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Several of the transcription factors effective on
the COX-2 gene are known to be stimulated by
inflammatory cytokines. Other cytokines and
corticosteroids can alter the half-life of the
inherently unstable mRNA, either increasing or
decreasing translation into protein. For the
protein itself, one option is to control the
provision of substrate arachidonic acid (AA),
although the most obvious regulator of activity
would be a selective COX-1 or COX-2 enzyme
inhibitor. All these possibilities, considered in
more detail below, are summarized in Fig. 1.
Regulation by inflammatory factors
A great variety of agents, mostly derived from
inflammatory situations, have been used to
induce COX-2 activity. The most frequently used
inducing stimuli are IL-1 and lipopolysaccharide
(LPS; used here as a synonym for bacterial
endotoxin) and not as might have been ex-
pected the inflammatory stimuli often used for
in vivo models, carrageenin64’68-71 or
72 These and other stimuli used with zymosan.
human cells are listed in Table 1.
(i) Cytokines
Although IL-1 might be considered a model
stimulus for the local induction of COX-2 in
arthritis and LPS for the cardiovascular effects
of the systemic induction of COX-2, these two
stimuli are, in vivo, closely related as the effects
of LPS are consequent on the production of
TNFcz and IL-1 from a range of cell types.
(+)
Free radicals
Protein kinases
Transcription factors (NFkB, NF-IL6)
Endotoxin
Pro-inflammatory cytokines (IL- 1, TNFa)
Mitogens
DNA
(-)
Protein kinase inhibitors
Anti-inflammatory cytokines (IL-4, IL- 10)
IL-1
Arachidonic acid
(+)
Phospholipase induction
(-)
Dexamethasone
Phospholipases
mRNA
COX-2 protein
PGs
Dexamethasone
Protein synthesis inhibitors
COX-2 inhibitors
FIG. 1. Control of PG synthesis by regulation of COX-2 induction and action. This figure outlines the different stages at
which modulation of COX-2 synthesis or function leads to alteration of the biological endpoint, production of PGs.
Stimulatory factors (/) are shown on the left and inhibitory factors (-) on the right hand side. As discussed in the text,
changes in the production of mRNA (transcription) by free radicals, protein kinases and cytokines are all finally mediated by
changes in transcription factors. Because mRNA for COX-2 is inherently short-lived, alterations in its biological half-life can
also significantly affect the amount of COX-2 protein synthesized. Protein synthesis inhibitors (cycloheximide) are included
in this scheme for completeness but are not considered any further in the text as a means of regulating COX-2 levels. Note
that factors affecting phospholipase induction or action could independently or co-operatively influence PG synthesis by
altering the amounts of endogenous AA available to COX-2. The levels of PG production in vivo under physiological or
pathological conditions will reflect the sum of changes in COX-2 and phospholipase activities. Intervention with COX-2
inhibitors allows exogenous control, overriding the endogenous mechanisms.
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Table 1. Stimuli known to induce COX-2 mRNA, protein or
activity in human cells
Stimuli Reference
LPS 17, 76, 99,108, 128, 130, 191-193
TNF 89, 193, 194
IL-1 126, 127, 139, 143, 148, 157, 160,
171, 194-199
EGF 88, 89, 91, 200
PDGF 200, 201
TGF(z, I 88, 89, 91
Phorbol ester 17, 148, 157, 202-204
Pregnancy 142, 203, 205, 206
Parturition 207-212
The references given are restricted to cells and tissues of human
origin and to papers published in 1994, 1995 and early 1996. These
are given as a guide to the range of systems (stimuli, cells, tissues
or in vivo) used and not as a complete list of all the work on COX-2.
Differences between the effects of LPS and IL-1
in cultured cells will clearly depend on the
ability of the cell line to release IL-1 in response
to LPS; such differences are less likely in vivo
or ex vivo where a wide range of cell types
have been exposed to the inducing agent. How-
ever as at least two cytokines, IL-10 and IL-4,
decrease induction (see below), their synthesis
in vivo following IL-1 or LPS treatment could
modify the final level of COX-2 activity attained.
In endothelial cells COX-2 is induced readily
by LPS, in some cases through the release of
73 76 TNF, PDGF and other cytokines. However
the initial stage of this process, the binding of
LPS to the cell membrane, is still unclear as
endothelial cells do not express the particular
LPS-binding membrane proteins (CD 14) that
may be used as receptors on leukocytes,77-v9 a
major cell type responding to LPS with induc-
tion of COX-2. There are some indications that
soluble forms of CD 14 are involved in the
mediation of responses to LPS in endothelial
ceils.
77,80
Whereas most cytokines so far studied in-
crease induction of COX-2, there are examples
of inhibition by cytokines. Two interleukins, IL-
10 and IL-4, already known to antagonize other
effects of ’pro-inflammatory’ cytokines,81’82 de-
creased COX-2 levels in monocytes stimulated
by LPS or Con A, 79’83’84 but in mast cells,85’86
IL-IO potentiated, whereas IL-4 still inhibited,
induction of COX-2 by c-kit ligand and IL-1. It is
possible that this discrepancy in the effects of
IL-10 is related to the cell types involved; more
studies would be needed to define such a
selectivity.
The TGF proteins, TGF and TGF, present
conflicting results for analysis. As might be
expected from its mitogenic activity, TGFx was
able to stimulate COX-2 production in epith-
elia
87 and to increase PGE2 output in human
amnion cells and in osteoblasts.88’89 TGF
synergized with IL-1 or TNFc9’91 to increase
PG output, perhaps because TGFc can also
induce IL-1 receptors. 91
Although TGF potentiated the induction of
COX-2 caused by phorbol ester in fibro-
blasts,92’93 it had no effect when given alone. In
macrophages, 94 the same cytokine inhibited the
induction of COX-2 by LPS, more in keeping
with its general anti-inflammatory profile. The
apparent divergence of the effects of TGF[ may
be more readily rationalized on the basis of cell
types; for an overall anti-inflammatory and
wound-healing effect, it would be reasonable to
de-activate leukocytes and to stimulate fibro-
blasts at the same time. TGF also affects NOS
induction in a range of cells95 but here the
majority of the results show a suppression of
iNOS synthesis. The down-regulation of two
major components of the inflammatory process
would contribute importantly to the anti-inflam-
matory action of this cytokine.
(ii) PGs
The PGs themselves are inducing agents, as
directly shown in osteocyte cultures96-98 or by
inference from the effects of COX in-
hibitors.87’99’1 In osteoblastic cell (MC3T3)or
calvarial cultures, PGE2, PGF2, PGD2 and ilo-
of PGI2) all induced prost (a stable analogue
COX-2 mRNA and protein
96-98 and indometh-
acin decreased COX-2 induction. Exogenous
PGE2 also stimulated COX-2 expression in
mouse macrophages treated with LPS.
1 In
these cells and in two other cell systems, rat
epithelial cells stimulated with TGF and phor-
bol ester and in human PMNs stimulated with
LPS, COX inhibitors (indomethacin or sulindac
sulphide) decreased COX-2 induction. 87’99 The
positive feedback implied in these systems
contrasts sharply with the negative feedback
loops more usually found in inflammatory con-
ditions where PGE2 and other agonists that raise
cAMP, actually decrease cytokine secretion from
102 104 macrophages and lymphocytes. Indeed
the breaking of this loop with COX inhibitors
(NSAIDs) in chronic inflammation is believed to
increase cytokine production and subsequent
degradation of joint cartilage while relieving
pain and oedema; thus symptomatic benefit is
undermined by a continuing or even acceler-
105,106 ated disease process.
(iii) Free radicals and nitric oxide
Another totally different class of compounds
associated with inflammatory situations are the
reactive oxygen intermediates or oxygen de-
rived free radicals (ODFR), such as superoxide
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anion (O) and the hydroxyl radical (OH-). A
role for these species in the induction of COX-2
has also been proposed.17’18 These highly
reactive chemical species are present at sites of
inflammation, leukocytes generate ODFR in the
phagocytic process (the oxidative burst) and
NO is another free radical, present during
inflammation, synthesized by iNOS and capable
of interacting with the ODFR to increase free
radical actions. Thus, there are many opportu-
nities for interactions between these radicals
and COX-2. In rat mesangial cells following LPS,
IL-1 or TNFct, radical scavengers (thioureas) or
other antioxidants inhibited the usual increase
in COX-2 mRNA, COX-2 protein and PGE2
synthesis.
17 The effects were selective in that
induction of other proteins (chemokines) by
LPS or of COX-2 by other stimuli (phorbol
esters, serum) were not similarly inhibited. At
present, the actual mechanism of the inter-
action between the ODFR and the transcription
of the COX-2 gene is not fully known, although
ODFR are known to activate NFkB,19’11 one of
the transcription factors active on the COX-2
gene. However, in the rat the COX-2 gene may
not exhibit a binding site for this transcription
factor. 19,21
Another free radical associated with inflamma-
tion is nitric oxide (NO) and its effects on COX
activity remain difficult to summarize briefly.
Both enzymes, COX and NO synthase (NOS),
have inducible isoforms, which are induced in
inflammatory situations by the same cytokines
and both genes belong to the family of immedi-
ate early genes. Thus interaction between these
two enzyme systems is highly likely; the diffi-
culty arises from the outcome of that inter-
action. There was potentiation of PG output in
the presence of NO
11-115 apparently by direct
interaction of NO with the haem in COX
protein,116 although this interpretation has been
questioned.liT,118 The opposite effect, inhibition
of PG output .b. NO, has also been observed in
macrophages. Action of PGs on NO output is
less frequently encountered12’121 although such
effects might be deduced from the interactions
of raised cAMP with NO output.
122-124 In one
case a truly reciprocal relationship, with PGs
inhibiting NO output and NO inhibiting PG
output, by which a constant level of vasodilator
tone may be maintained has been described in
human saphenous vein.125 This last example is
unlikely to involve induced forms of either
enzymes and is perhaps less relevant to the
present discussion but it does illustrate the
range of interactions possible between these
enzymes. The most valid conclusion would
seem to be that there is no generalization and
that each situation with its particular combina-
tion of species, cell type and stimulus has to be
evaluated individually.
(iv) Contribution ofphospholipases
A potential source of confusion in the interpre-
tation of experiments involving COX-2 induc-
tion is the simultaneous induction of PEA2
activit
most frequently with IL-1 as inducing
agent. 6,126-132 Increased PEA2 activity implies
increased provision of free AA which could be
as easily available to COX-1 as to COX-2. Thus
the final effect, increased synthesis of PGs, is
not necessarily due solely to increased COX-2.
One prediction from this co-induction is that
the effectiveness of inhibitors of COX-2 could
depend on the level of PEA2 induced at the
same time and that level could vary with the
nature of the major inducing agent (IL-1, PAF or
TNF) and with the cell type involved. The
localization of the human gene for cytosolic
PEA2 to the same chromosomal region as the
gene for COX-2 (lq25), raises the possibili_ty of
coordinate regulation of these enzymes.133’13
(v) Effects of corticosteroids
The major inhibitory mechanism affecting COX-
2 induction, both in terms of experimental
results and of pathophysiological relevance is
the action of corticosteroids, most frequently
demonstrated with dexamethasone (Dex). In
many conditions, susceptibility of the produc-
tion of PGs, enzyme protein or mRNA to
inhibition by Dex is used as clear evidence for
COX-2 induction. This simple conclusion is
however clouded by other actions of Dex
including the inhibition of the induction of
PEA2132 and inhibition of PEA2 activity itself via
lipocortin. 135’136 For instance over 20 years ago
it was shown that the output of PGs from
freshly isolated lungs from untreated guinea-
pigs, conditions in which COX-2 induction
should be minimal, was decreased by infusions
of Dex.17 There is nevertheless clear evidence
for decreased induction of both COX-2 protein
and mRNA in the presence of Dex. 25’93’13g-141
There are also a few examples of cortico-
steroids increasing PG production. The mRNA
for COX-2 but not that for COX-1 was increased
20-fold in human amnion cell cultures exposed
to Dex for 16 h.142 Interestingly, oestradiol and
progesterone did not increase COX-2 mRNA but
cortisol did. More typically, in human decidual
tissue, Dex and progesterone were inhibitory.143
As with other examples of corticosteroid inhibi-
tion of mRNA, the mechanism of action of Dex
on COX-2 induction is poorly elucidated; either
increased degradation of an already short-lived
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mRNA8,44 or decreased transcription are possi- Regulation by substrate
ble contributors to the overall affect.
One of the continuing controversies in the
analysis of COX action centres on the influence Regulation via intracellular signalling of different sources of substrate on activity.
Tyrosine kinases play important roles in the There is a clear difference between the utiliza-
intracellular signalling pathways for COX-2 in- tion of endogenous and exogenous AA in that
duction in a range of cells; in endothelial cells, the supply of endogenous substrate is con-
epithelial cells and macrophages this was trolled by enzymes outside the COX cascade,
demonstrated with tyrosine kinase in- chiefly by the balance between phospholipid
hibitors7’74’45-48 and in mesangial cells by hydrolysis and re- or trans-acylation. 161’162 The
measurement of protein tyrosine phos- levels of endogenous substrate can be increased
phorylation.
72,149-151 The oncogene v-src en- and PG output consequently stimulated in a
coding a tyrosine kinase is by itself enough to number of cells and tissues (without induction
cause COX-2 induction in T cells.44 Whereas of COX-2) by agents such as thrombin, hista-
163 the induction by EGF 25 probably utilized the mine, brad kinin, PAF or the crosslinking of Y 164 receptor tyrosine kinase, the kinases used by IgE receptors. Ths stimulation s charactens-
other inducing agents have not yet been clearly tically of short duration, less than 30 min and
identified. However the inhibition by tyrosine there is no doubt that endogenous substrate is
kinase inhibitors such as erbstatin and genistein utilized by COX-1 to increase PG synthesis. The
73 145 146 152 of both COX-2 and iNOS induction experiments in which COX-2 utilizes endogen-
offers a new mode of anti-inflammatory action, ous substrate are characteristically of longer
which would have the advantage of not acting duration (6-24 h) and entail incubation of cells
on constitutive enzyme activities. Such an effect with an inducing agent such as LPS, TPA or
may contribute to the anti-inflammatory proper- PDGF which is present throughout the incuba-
ties of leflunomide5 which was shown to tion. The PGs accumulated over these longer
inhibit the EGF-stimulated tyrosine kinase,154 periods are increased many-fold in the presence
the Src tyrosine kinases55 and the synthesis of of the inducer molecule, relative to those in
PGE2 induced by LPS in human leukocytes. 99 control incubations. Most of the inducing agents
Another signalling pathway, via protein kinase will increase phospholipase action as well as
C (PKC), also appears to be involved but here inducing COX-2 protein.126’128-’165 Again
the net effects of stimulating PKC activity are there is no doubt that COX-2 can utilize
more variable. In most cases, increased PKC endogenous substrate to form PGs.
activity was associated with induction of COX- The problems appear with the use of exogen-
87 147 149 156 158 2 but in alveolar macrophages, ous substrate. Addition of exogenous AA (10-
inhibition of PKC with staurosporine caused 30 btM) to systems containing COX-1 leads to
COX-2 induction.59 Another confusing factor is increased output of PGs. However in some
the well-established down-regulation of PKC on preparations where both COX-1 and COX-2 are
continued stimulation by phorbol esters. In the present, the induced enzyme appears to con-
present context this was illustrated by the tribute no additional amount of PGs over that
stimulation of COX-2 mRNA by 5HT (mediated seen with COX-1 alone, leading to the proposi-
via 5HT2 receptors and PKC activation)or by tion that COX-2 does not utilize exogenous
short exposure to phorbol ester. However pre- aa. 92 Two comments are relevant. First, this
incubation with phorbol ester followed by 5- ’inaccessibility’ of exogenous AA is not a uni-
HT, abolished induction of COX-2 mRNA.149 versal finding; in a variety of cells, 74’75’158’166’167
These kinase pathways are not exclusive and induction of COX-2 did lead to an increase in
in mesangial cells with 5HT as stimulus both PG output from exogenous substrate. Second,
PKC and tyrosine kinase mediate the induction the use of exogenous AA involves incubation
of COX-2 mRNA.49 In human skin fibroblasts for short times, typically 10 min, compared with
after IL-1 stimulation, PKC appeared to be the 6 h incubations to show COX-2 induction. 92
major protein kinase with only minor contribu- Within 10 min over 100 ng PGE2/ml was gener-
tions from PKA or tyrosine kinases.16 However ated, whereas over 6 h there was accumulation
in ovarian tissue both PKA and PKC were of only about 20ng/ml. An equally plausible
activated during LH and GnRH stimulation of explanation would be that although COX-2 was
COX-2.56 Other intracellular second messen- induced several-fold, the actual amounts of
gers identified in osteoblasts include cAMP and COX-2 protein were still low relative to the
PLC, stimulated by PGE2 or iloprost (a stable amount of COX-1 present. It is thus not possible
analogue ofPGI2) and PGF2a respectively. 96 to come to a definite conclusion on the
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selective accessibility of exogenous substrate to
either isoform on the basis of these experi-
ments.
A variation of this hypothesis was the conclu-
sion drawn from work with only endogenous
substrate in mast cells.
164 Here release of PGD2
and COX-2 protein were induced by incubating
the mast cells with a mixture of cytokines.
Incubation in this medium for 5-10 h increased
PGD2 output many-fold to about 5-10 ng/ml.
’Acute’ stimulation of PGD2 biosynthesis by the
crosslinking of IgE receptors in these cells was
not increased until after 24 h incubation with
the cytokine mixture, by which time the COX-2
protein had fallen again to near normal levels.
There was certainly no increase in the ’acute’
release of PGD2 at the time of peak COX-2
induction. From this the authors concluded that
the induced COX-2 did not have access to the
increased AA released during IgE stimulated
PGD2 synthesis and that only COX-1 was
utilized, even when COX-2 had been induced,
to form PGs subsequent to IgE stimulation. A
comparison of the times over which these
experiments were performed shows that the
IgE stimulation provided about 5 ng PGD2/IO6
cells in 10 min whereas the cytokine stimula-
tion took 10 h to provide 10 ng/106 cells. On
this basis the induced COX-2 would provide
about 0.2 ng in 10 min; this contribution would
be rather difficult to detect against the total of
5 ng produced. The authors may be correct in
postulating different coupling of stimuli to the
isoforms but the experimental results are not an
adequate test of their hypothesis. Indeed in a
more recent paper from this group, the ’stimu-
lus selective’ linkage of COX-1 or COX-2 action
has been replaced by a ’time selective’ hypo-
thesis.168
If distinct pools of substrate for COX-1 and
COX-2 do exist they are more likely to be
defined on a spatial basis than on a simple
endogenous/exogenous substrate criterion. In-
deed if COX-2 shares the general three-dimen-
sional structure proposed for COX-l,
31 with the
membrane anchors defining the entrance to the
active site tunnel which guides AA cleaved from
the adjacent membrane up to the oxidative site
of the enzyme, it is not immediately obvious
how one isoform could favour exogenous AA
over the freshly hydrolysed product of the
underlying ER membrane. However this model
of COX action would assume a phospholipase
in close proximity to the COX protein and a
more likely basis of selectivity is in the phos-
pholipase activated to supply endogenous AA.
Although most emphasis has been placed on
PEA2 in this context, the action of either PLC or
PLD can also give rise to free AA. Different
ligands for cell membrane receptors will acti-
vate these phospholipases differentially. Further-
more, each phospholipase has its own substrate
selectivities and the distribution of the phospho-
lipids is not uniform throughout all mem-
branes.162 There is also evidence for a selective
locus of COX-2 in the nuclear membrane, apart
from the location in the ER demonstrable for
both isoforms.5 Thus a combination of which
phospholipase is activated by which stimulus
and which phospholipid is closest to a particu-
lar COX protein might appear to give a degree
of selectivity between isoforms in terms of the
substrate.
Selective Inhibition of COX-2
One disadvantage of regulating COX-2 by inter-
ference with the processes of transcription,
translation or intracellular signalling pathways is
that, at present, selectivity of effect is low. This
is well recognized for the corticosteroids which
will prevent induction of many proteins apart
from COX-2 and could be equally true for
antagonists of or interference with, transcrip-
tion factors such as NFkB or NF-IL6169 or for the
inhibitors of tyrosine kinase. Logically the most
selective effect would be attained by inhibition
of the enzyme protein and this consideration
coupled with the effectiveness of COX inhibi-
tors already known has led to an extensive
search for new inhibitors with a selective action
on COX-2. Particularly, such selective agents
should be free of the most significant side
effects associated with COX-1 inhibition, gastric
ulcers and nephropathy.
Assessment of selectivity
The initial stages of this search were concerned
with assessment of the selectivity of the known
NSAIDs or COX inhibitors and very soon estab-
lished one major difficulty in the analysis, a
marked variation in the selectivity ratio (IC50 for
COX-I:IC50 for COX-2) for any given compound;
a high ratio representing selectivity for COX-2
inhibition. For instance, ratios for indomethacin
ranged from 20170 to 0.1.171 This variability is
due to variation, at every level, in the experi-
mental conditions of the assays. Different types
of cell are used, derived from different species,
as whole cells, homogenates, purified extracts
or recombinant proteins expressed in bacterial,
insect or animal cells. Further variation is intro-
duced in the time of pre-incubation with
inhibitor, the concentration of exogenous sub-
strate or the use of endogenous substrate. The
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last three factors contribute significantly to the trations of AA could thus be higher, providing
marked differences in selectivity. For instance more competition for the binding of inhibitor.
with 10 min pre-incubation, indomethacin at Even the time dependent irreversible inhibitors
1.6 bM completely abolished COX-2 activity will show some reversal of inhibition when
whereas COX-1 activity suffered only 50% in- exposed to high AA concentrations. 42
hibition. However, with no pre-incubation, indo- The value of a model system must lie in its
methacin had an IC50 of 13.5 bM for COX-1 ability to predict compounds with selective
whereas for COX-2 the IC50 was over COX-2 inhibition in vivo and one test of that
1 000 l,m.
172 Clearly two very different selectiv- value is to assess the compounds already known
ity ratios would be calculated from IC50 values to exhibit such activity alongside those NSAIDs
obtained under these two experimental condi- with the worst side effect profiles.
75 Thus
tions. Time-dependent inhibition of COX-2 but compounds such as NS398, SC58125 and
not of COX-1 by NS 398 was the major reason CGP28238 must be clearly separated from
for its selectivity with human recombinant NSAIDs such as piroxicam, azapropazone or
enzymes.4’44 A similar differential time-depen- ketoprofen. Most model systems achieve this
dency was reported for CGP28238, another separation and will probably be efficient
COX-2 selective inhibitor.
42 This feature is not screens for selective COX-2 inhibitors. However,
the sole determinant of selectivity as several it must be remembered that over the last 25
COX-1 inhibitors also show time-dependent years, reliance on in vitro screening with COX
inhibition of either isoform. 42’44’45 purified from ram seminal vesicle (now known
Another source of variability with important to be almost entirely COX-l) must have led to
practical consequences is the nature of the the rejection of many COX-2 selective inhibitors
enzyme system used, i.e. in whole cells, homo- before they could be tested in vivo and a
genates or purified enzymes. Many groups have similar absolute reliance on a single in vitro
used human platelets as a source of COX-1 and screen for COX-2 could lead to similar mistakes.
a variety of cells (renal mesangial cells, macro-
phage cell lines, peripheral blood monocytes) Progress in develomn o selective stimulated with IL-1 or LPS to provide COX-2. inhiBitors The IC50 values for indomethacin for whole cell
preparations vary but are always lower than There were at least two examples of possible
those reported for cell free preparations.7 This selective COX-2 inhibitors in the literature; both
is true also for selective inhibitors; the IC50 for exhibited a good anti-inflammatory effect in
CGP28238 against COX-2 was 15 nM in whole vivo with little or no inhibition of the standard
cells but 750 nM even after prolonged preincu- COX preparation from ram seminal vesicle
bation with purified enzyme.
42 Similarly, in- together with low ulcerogenic activity. The first
creased potencies (lower IC50) have been noted of these compounds, nimesulide, was patented
for aspirin, ibuprofen and even salicylate in over 20 years ago and has been available latterly
whole cells compared with values obtained in in several European countries as an out-of-
broken cell or purified enzymes.74 There are patent, non-prescriltion analgesic and anti-in-
no obvious explanations for this phenomenon, flammatory agent. The other, CGP28238, is
Preferential concentration of the inhibitor in closely related in structure (see Fig. 2) and was
lipid of the ER membrane to give a locally first reported in 1989.
77 A third close relative,
higher concentration than in the bulk solution NS398, was described many years later as a
would not explain why inhibitory potency is selective inhibitor of COX-2.178
lost in broken cells as crude homogenates after Subsequent development has led to DuP
centrifugation would contain enzyme still at- 697,79 SC 58125
8 and L-745,337,
8 with
tached to fragments of ER. One possibility is many other similar compounds less extensively
that in whole cells the concentration of free AA studied.42’82-85 The most striking feature of
is kept low by restraining phospholipase activ- this new generation of NSAIDs is that none of
ity (through low intracellular calcium, for in- them are carboxylic acids, like the ’old’ NSAIDs,
stance) and increasing re- or trans-acylation into and all have the sulphone or sulphonamide
lipid.’2 Thus, the initial binding of the grouping. The simplest (and perhaps simplistic)
inhibitor to the enzyme in whole cells takes inference from this is that the selective COX-2
place with little or no competition from the inhibitors bind to a site that is different from
substrate AA, allowing a maximal inhibitory that used by the ’old’ NSAIDs7 and, as
effect. In a broken cell preparation the calcium proposed earlier, would suggest a structure
concentration is much higher than the normal unique to the COX-2 protein which, at first
intracellular level, lipase activities and concen- sight, is most likely to be the 18-amino acid
316 Mediators of Inflammation Vol 5 1996Cyclooxygenase-2 and its regulation in inflammation
Meloxicam
CH3
CONH
qS.NCH
DuP 697
o>
CH3
SBr
NS-398
O
NO2
H N
CH3--- S--"O
O
CGP 28238
F
F
CH3---SO
II
O
SC 58125
o% o
NN
CF
L-745,337
F O
Na S*,
N
CH3---- S O
II
O
Nimesulide
O,
NO2
H N
CH3-.-.-- SO
O
FIG. 2. Chemical structures of selective inhibitors of COX-2. All the compounds shown have exhibited inhibitory selectivity
towards COX-2 in a range of systems (see Table 2). The sulphonamide grouping is present in all except meloxicam in which
it forms part of a cyclic structure. None of these compounds has a carboxylic acid grouping characteristic of the ’older’
NSAIDs.
insert at the C-terminus. It is important to note
that neither the ’old’ nor the new selective
COX inhibitors affect the peroxidase activity of
the proteins, implying that the binding of COX-
2 inhibitors, like that of COX-1 inhibitors, does
not disturb the three-dimensional structure of
the protein on the ’other’ side of the haem
ring.
29,35,36
In spite of all the reservations outlined above,
the search for selective COX-2 inhibitors has
been remarkably successful. To some extent this
reflects the efficacy of the exemplar compound,
nimesulide, but all the subsequent develop-
ments exhibit the predicted properties. They all
have good selectivity in vitro with pure en-
zymes or in cell systems with ratios of IC50
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favouring COX-2 in all assays and some values
are shown in Table 2. Furthermore they exert
anti-inflammatory activity in a range of models,
acute and chronic, as well as anti-pyretic and
analgesic activities and at these doses there is
little or no gastric ulceration. Clearly, it is
possible to achieve selective inhibition of COX-
2 and now it seems only a matter of refining the
effective structures to combine the highest
selectivity with the best pharmacokinetics and
provide compounds for clinical evaluation.
One result of the selectivity of COX inhibition
coupled with a better understanding of the
conditions in which COX-2 can be induced is
that it may now be reasonable to use COX-2
inhibitors in therapeutic areas such as endotox-
in shock or asthma where the ’old’ NSAIDs
were ineffective. The greater potency against
COX-2 together with lack of toxicity on sto-
mach and kidney could allow a reduction in PG
output via the induced enzyme while allowing
the ’beneficial’ output from constitutive COX-1.
Another potential therapeutic area of consider-
able promise for COX-2 inhibitors is suggested
by the negative correlation between colon
cancer and NSAIDs;
186 recently aspirin was
shown to reduce the risk of colorectal cancer
by almost half. 187 The crucial observations were
that the COX-2 isoform was present only in
malignant tissue188’189 and conferred resistance
to apoptosis,63’19 implying an important role
for COX-2 in neoplastic growth.
The side effects or toxicity of COX-2 inhibi-
tors are not easy to predict; certainly those of
the ’old’ NSAIDs should be absent, by defini-
tion. From the evidence of the knock-out
mice,64’65 the major toxicities will be on the
Table 2. Selective COX-2 inhibitors
reproductive system, on fertility and foetal
development. Whereas decreased fertility, as
long as it is reversible, may not be an unaccep-
table side effect, developmental defects, espe-
cially in the kidney, would most certainly
prevent the use of COX-2 inhibitors during
pregnancy and thus extensive testing for poss-
ible teratogenic effects would be required.
Summary
Elucidation of the regulation of COX-2 provides
an instructive example of the interaction be-
tween molecular biology and applied pharma-
cology. The basic science of the identification of
the isoforms and the stimuli for induction was
rapidly transformed into a new and powerful
therapeutic concept, NSAIDs without the usual
side effects. We now know a great deal about
COX-2 from the gene to the crystal structure of
the protein, its substrate sites and its intracellu-
lar location, much more than about many other
enzymes of pharmacological importance. How-
ever in one significant aspect this encouraging
utilization of molecular biology has failed; for all
our knowledge, the design of selective inhibi-
tors has not been based on a careful study of
the structure of the protein and its interactions
with substrate but, as in the past, on chemical
variations of a molecular structure, found em-
pirically to be effective. Moreover, deductions
based on the knock-out mice would deny much
of the equally empirical evidence correlating
inflammation with COX activity.
Nevertheless it was molecular biology that
disclosed the important place of COX-2 in
reproduction, that raised new possibilities for
Compound alC50 for COX-2 bRatio IC50 CAnti-inflammatory doses dUIcerogenic References
(nM) COX-1:2 (mg/kg) potential in vivo
(mg/kg)
acute chronic
Nimesulide 13 13 3 0.2 100 213, 214
CGP 28238 15 5000 2 0.05 30 171, 177
NS 398 100 260 5 > 000 44, 215
SC 58125 50 > 2000 2 > 600 180
L 745337 23 > 400 2 > 30 181
Meloxicam 2 3 3 0.1 2.5 216, 217
DuP 697 10 80 0.03 0.2 > 400 45, 179
Indomethacin 6 0.03 1.5 O. 8 215, 216
Piroxicarn 175 0.03 2.7 0.6 1.1 216, 217
aThese values were obtained in vitro with whole cells, purified native or recombinant enzymes.
bA high value here denotes high selectivity for inhibition of COX-2.
CThe acute model was usually paw oedema, sometimes carrageenin pleurisy. The chronic model was usually adjuvant arthritis. The values
shown are ED50 or ED30 doses in each model.
dThese values represent the threshold dose for gastric damage or the highest dose at which damage was still absent.
Bearing in mind the diversity of test systems used, the important values in the table are not the absolute potencies of the compounds in any
given test system but the ratios, firstly of IC50 COX-I:COX-2 which gives some indication of selectivity in vitro (see text for further comment)
and then the ratio of the ED50 in chronic inflammation and the ulcerogenic dose, giving an estimate of in vivo selectivity. Note that the last
two compounds in the table (shown in italics) are examples of the ’old, non-selective’ NSAIDs. In fact these were quite selective for COX-l, as
shown by the values for the IC50 ratios.
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the physiological role of COX-1 and that eluci-
dated the correlation between COX-2 and neo-
plastic growth. In this last context, there is an
intriguing possibility for which there is no
direct evidence yet but which is entirely as-
sessable with molecular biological techniques,
namely that COX-2, like the products of other
immediate-early genes, has effects on gene
transcription and/or translation that do not
entail the oxidation of AA to PGs. In all these
roles and in the new ones to come, the analysis
of regulatory mechanisms, physiological, patho-
physiological and pharmacological, will remain
central to scientific and clinical progress.
Note Added in Proof
The X-ray crystal structure of human COX-2
desribed by M. Browner et al. is to appear in
Nature (Structural biology) in November 1996.
Two further descriptions, of murine COX-2 by
R. G. Kurumbail et al. and of the human protein
by B. M. McKeever et al. were given at a
meeting in Vienna in September 1996 and have
been submitted for publication. All three re-
ports include discussions of the binding sites
for selective inhibitors of COX-2.
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